Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vasomedical Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Jack Ucci who wrote (941)	6/15/1998 2:37:00 PM
From: Harvey Barish	Read Replies (1) \| Respond to of 1605

Vasomedical Reports a High Rate of Improvement With EECP Therapy in Commercial Settings; Reimbursement Coverage Increasing WESTBURY, N.Y.--(BW HealthWire)--June 15, 1998--Vasomedical Inc. (NASDAQ:VASO) reports that an abstract titled "Quality of Life Benefits in the Enhanced External Counterpulsation Clinical Consortium" has been accepted for presentation on August 23rd at the scientific meeting of the European Society of Cardiology in Vienna, Austria. The abstract reports functional improvements in about 70 percent of patients after EECP(R) therapy in commercial centers. The abstract is an analysis of Vasomedical's in-house patient registry in which more than 1,000 patients have now been entered. EECP(R) treatment centers establish how angina limits patients' ability to function before and after a full course of EECP(R) therapy using the Canadian Cardiovascular Society Classification for functional status, a standardized method of grading the severity of angina. These data are sent by EECP(R) treatment centers to Vasomedical on a voluntary basis for compilation and analysis. Vasomedical's Vice President of Marketing and Clinical Affairs, Anthony E. Peacock, commented, "Acceptance of this report by the European Society of Cardiology recognizes the important contribution that this database can make to the accumulating evidence supporting the remarkable effectiveness of EECP(R) treatment. Analysis of the data have remained consistent since documentation began with approximately 70 percent of patients improving at least one class and 20 percent improving at least two classes. These findings parallel closely the results of clinical studies conducted in academic institutions to validate the efficacy of EECP(R) treatment scientifically. New therapies must also prove themselves to be robust in the everyday world. Data such as these help confirm that EECP(R) therapy produces predictable outcomes irrespective of the locale." In addition to satisfaction with clinical results, treatment providers also report that nearly 60 third-party payers have provided coverage for EECP(R) therapy on a case-by-case basis, a substantial increase from the 35 reported by the company in December 1997. The company recently announced a $3.5M capital infusion that will enable it to undertake specific marketing initiatives, including customer support programs to further increase patient recruitment and insurance reimbursement, as well as seeding programs in capitated HMO settings. Vasomedical (www.vasomedical.com) is a medical technology company devoted to the development, manufacture and commercialization of innovative and cost-effective cardiovascular products and processes. (Except for historical information contained in this news release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate", "believe", "estimate", "expect" and "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the company's management, as well as assumptions made by and information currently available to the company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; and the risk factors reported from time to time in the company's SEC reports.) CONTACT: Vasomedical Inc. Anthony E. Peacock, 516/997-4600 ext.120 Copyright 1998, Business Wire. All of the releases provided by Business Wire are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who are solely responsible for their content, accuracy and originality. All reproduction, other than for an individual user's reference, is prohibited without prior written permission. c Copyright 1998, The Nasdaq Stock Market, Inc. All Rights Reserved. Please read our Disclaimer, Trademarks, and Privacy Statement.